Reversible anti-TNFα treatment induced dementia: A case report

Camille Hou; Emmanuel Azzi; Anne Salmon; Marie-Noëlle Osmont; Aleth Perdriger

doi:10.1016/j.jbspin.2020.06.017

Reversible anti-TNFα treatment induced dementia: A case report

Joint Bone Spine. 2021 Jan;88(1):105044. doi: 10.1016/j.jbspin.2020.06.017. Epub 2020 Jul 1.

Authors

Camille Hou¹, Emmanuel Azzi², Anne Salmon¹, Marie-Noëlle Osmont³, Aleth Perdriger⁴

Affiliations

¹ Neurology department, Rennes University, Rennes, France.
² Rheumatology department, Rennes University, CHU de Rennes Hôpital Sud, 35056 Rennes, France.
³ Pharmacovigilance, Pharmacoepidemiology and Drug Information Center, Department of Clinical Pharmacology, Rennes University, Rennes, France.
⁴ Rheumatology department, Rennes University, CHU de Rennes Hôpital Sud, 35056 Rennes, France. Electronic address: aleth.perdriger@chu-rennes.fr.

PMID: 32622041
DOI: 10.1016/j.jbspin.2020.06.017

Abstract

We report the first case of a reversible rapidly progressive dementia occurring in a patient with ankylosing spondylitis, a few months after the beginning of a TNFα inhibitor treatment (TNFi). The exhaustive neurologic explorations were negative. No etiology was found to explain dementia. The dementia slowly improved after TNFi withdrawal. The chronology of this observation suggests a responsibility of the TNFi in the dementia manifestations.

Keywords: Anti-TNFα; Drug induced dementia; Rapidly progressive dementia.

Publication types

Case Reports

MeSH terms

Antirheumatic Agents* / adverse effects
Dementia* / chemically induced
Dementia* / diagnosis
Humans
Spondylitis, Ankylosing* / drug therapy
Treatment Outcome
Tumor Necrosis Factor Inhibitors* / adverse effects

Substances

Antirheumatic Agents
Tumor Necrosis Factor Inhibitors